Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5846148 | 0.82 | KMT2A (0.33) | KMT2A | |
| SCHEMBL919534 | 0.64 | DRD3 (0.45) | KMT2A | |
| SCHEMBL5477108 | 0.64 | GAA (0.40) | KMT2A | |
| SCHEMBL14408262 | 0.59 | CHRM2 (0.46) | KMT2A | |
| SCHEMBL6304673 | 0.59 | PER2 (0.39) | — | |
| SCHEMBL5081884 | 0.58 | L3MBTL1 (0.46) | KMT2A | |
| SCHEMBL1341814 | 0.57 | ALDH1A1 (0.44) | KMT2A | |
| SCHEMBL3988129 | 0.56 | CHRM2 (0.47) | KMT2A | |
| SCHEMBL3468977 | 0.56 | POLB (0.31) | — | |
| SCHEMBL5810929 | 0.56 | ALDH1A1 (0.42) | KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11548910-B2 | Oligonucleotide production method | NISSAN CHEMICAL CORPORATION (JP) | 2023-01-10 | — | — | US | disclosed |
| EP-3950698-A1 | METHOD FOR PRODUCING OLIGONUCLEOTIDE HAVING PHOSPHOROTHIOATE SITE | AJINOMOTO CO., INC. (JP) | 2022-02-09 | — | — | EP | disclosed |
| US-20220010348-A1 | METHOD FOR PRODUCING OLIGONUCLEOTIDE HAVING PHOSPHOROTHIOATED SITE | AJINOMOTO CO., INC. (JP) | 2022-01-13 | — | — | US | disclosed |
| WO-2020196890-A1 | METHOD FOR PRODUCING OLIGONUCLEOTIDE HAVING PHOSPHOROTHIOATE SITE | 味の素株式会社 | 2020-10-01 | — | — | WO | disclosed |
| US-20190169223-A1 | OLIGONUCLEOTIDE PRODUCTION METHOD | NISSAN CHEMICAL CORPORATION (JP) | 2019-06-06 | — | — | US | disclosed |
| EP-3378869-A1 | METHOD FOR PRODUCING OLIGONUCLEOTIDE | Nissan Chemical Corporation (JP) | 2018-09-26 | — | — | EP | disclosed |
| US-7022833-B2 | Process for the preparation of phosphorothioate triesters | AVECIA LIMITED (GB) | 2006-04-04 | — | — | US | disclosed |
| US-7019127-B2 | Solution phase synthesis of oligonucleotides | AVECIA LIMITED (GB) | 2006-03-28 | — | — | US | disclosed |
| US-20050240015-A1 | Solution phase synthesis of oligonucleotides | AVECIA LIMITED (GB) | 2005-10-27 | — | — | US | disclosed |
| EP-1272501-B1 | PROCESS FOR THE PREPARATION OF PHOSPHOROTHIOATE TRIESTERS | AVECIA LTD (GB) | 2004-05-06 | — | — | EP | disclosed |
| EP-1325927-A2 | Synthesis of oligonucleotides | Avecia Limited (GB) | 2003-07-09 | — | — | EP | disclosed |
| WO-2003045969-A1 | COUPLING REAGENT FOR H-PHOSPHONATE CHEMISTRY | AVECIA BIOTECHNOLOGY INC. (US) | 2003-06-05 | — | — | WO | disclosed |
| US-20030099981-A1 | Process for the preparation of phosphorothioate triesters | NITTO DENKO AVECIA, INC. | 2003-05-29 | — | — | US | disclosed |
| US-20030083490-A1 | Solution phase synthesis of oligonucleotides | AVECIA LIMITED | 2003-05-01 | — | — | US | disclosed |
| EP-1003758-B1 | SOLUTION PHASE SYNTHESIS OF OLIGONUCLEOTIDES | AVECIA LTD (GB) | 2003-04-09 | — | — | EP | disclosed |
| US-6506894-B1 | Phosphonation; oxidation in situ with sulfur transfer agent | AVECIA LIMITED (GB) | 2003-01-14 | — | — | US | disclosed |
| EP-1272501-A1 | PROCESS FOR THE PREPARATION OF PHOSPHOROTHIOATE TRIESTERS | Avecia Limited (GB) | 2003-01-08 | — | — | EP | disclosed |
| WO-2001064702-A1 | PROCESS FOR THE PREPARATION OF PHOSPHOROTHIOATE TRIESTERS | AVECIA LIMITED (GB) | 2001-09-07 | — | — | WO | disclosed |
| EP-1003758-A2 | SOLUTION PHASE SYNTHESIS OF OLIGONUCLEOTIDES | Avecia Limited (GB) | 2000-05-31 | — | — | EP | disclosed |
| WO-1999009041-A2 | SOLUTION PHASE SYNTHESIS OF OLIGONUCLEOTIDES | AVECIA LIMITED (GB) | 1999-02-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220010348-A1 | METHOD FOR PRODUCING OLIGONUCLEOTIDE HAVING PHOSPHOROTHIOATED SITE | RNGTT, NUDT1, ADAR | KMT2A 2596/4885 |
| US-20030083490-A1 | Solution phase synthesis of oligonucleotides | NUDT1, POLR2E, POLRMT | KMT2A 3491/4885 |
| US-20050240015-A1 | Solution phase synthesis of oligonucleotides | NUDT1, POLR2E, POLRMT | KMT2A 3491/4885 |
| US-11548910-B2 | Oligonucleotide production method | RNGTT, OSGEP, PHAX | KMT2A 2395/4885 |
| US-20190169223-A1 | OLIGONUCLEOTIDE PRODUCTION METHOD | RNGTT, OSGEP, PHAX | KMT2A 2395/4885 |
| US-20030099981-A1 | Process for the preparation of phosphorothioate triesters | OSGEP, NUDT1, PNKP | KMT2A 2625/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.